SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS by Malcovati, L, Stevenson, K, Papaemmanuil, E, Neuberg, D, Bejar, R, Boultwood, J, Bowen, DT, Campbell, PJ, Ebert, BL, Fenaux, P, Haferlach, T, Heuser, M, Jansen, JH, Komrokji, RS, Maciejewski, JP, Walter, MJ, Fontenay, M, Garcia-Manero, G, Graubert, TA, Karsan, A, Meggendorfer, M, Pellagatti, A, Sallman, DA, Savona, MR, Sekeres, M, Steensma, DP, Tauro, S, Thol, F, Vyas, P, Van de Loosdrecht, AA, Haase, DT, Tuechler, H, Greenberg, PL, Ogawa, S, Hellstrom-Lindberg, ES, Cazzola, M

Luspatercept in patients with lower-risk myelodysplastic syndromes by Fenaux, P, Platzbecker, U, Mufti, GJ, Garcia-Manero, G, Buckstein, R, Santini, V, Díez-Campelo, M, Finelli, C, Cazzola, M, Ilhan, O, Sekeres, MA, Falantes, JF, Arrizabalaga, B, Salvi, F, Giai, V, Vyas, P, Bowen, D, Selleslag, D, DeZern, AE, Jurcic, JG, Germing, U, Götze, KS, Quesnel, B, Beyne-Rauzy, O, Cluzeau, T, Voso, M-T, Mazure, D, Vellenga, E, Greenberg, PL, Hellström-Lindberg, E, Zeidan, AM, Adès, L, Verma, A, Savona, MR, Laadem, A, Benzohra, A, Zhang, J, Rampersad, A, Dunshee, DR, Linde, PG, Sherman, ML, Komrokji, RS, List, AF

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups by Haase, D, Stevenson, KE, Neuberg, D, Maciejewski, JP, Nazha, A, Sekeres, MA, Ebert, BL, Garcia-Manero, G, Haferlach, C, Haferlach, T, Kern, W, Ogawa, S, Nagata, Y, Yoshida, K, Graubert, TA, Walter, MJ, List, AF, Komrokji, RS, Padron, E, Sallman, D, Papaemmanuil, E, Campbell, PJ, Savona, MR, Seegmiller, A, Adès, L, Fenaux, P, Shih, L-Y, Bowen, D, Groves, MJ, Tauro, S, Fontenay, M, Kosmider, O, Bar-Natan, M, Steensma, D, Stone, R, Heuser, M, Thol, F, Cazzola, M, Malcovati, L, Karsan, A, Ganster, C, Hellström-Lindberg, E, Boultwood, J, Pellagatti, A, Santini, V, Quek, L, Vyas, P, Tüchler, H, Greenberg, PL, Bejar, R, International Working Group For Mds Molecular Prognostic Committee